About cormedix - CRMD
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.
CRMD At a Glance
CorMedix, Inc.
300 Connell Drive
Berkeley Heights, New Jersey 07922
| Phone | 1-908-517-9500 | Revenue | 311.71M | |
| Industry | Biotechnology | Net Income | 163.06M | |
| Sector | Health Technology | 2025 Sales Growth | 617.031% | |
| Fiscal Year-end | 12 / 2026 | Employees | 191 | |
| View SEC Filings |
CRMD Valuation
| P/E Current | 3.472 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 5.728 |
| Price to Sales Ratio | 2.996 |
| Price to Book Ratio | 2.274 |
| Price to Cash Flow Ratio | 5.34 |
| Enterprise Value to EBITDA | 5.654 |
| Enterprise Value to Sales | 2.995 |
| Total Debt to Enterprise Value | 0.159 |
CRMD Efficiency
| Revenue/Employee | 1,631,984.293 |
| Income Per Employee | 853,691.099 |
| Receivables Turnover | 1.82 |
| Total Asset Turnover | 0.626 |
CRMD Liquidity
| Current Ratio | 2.106 |
| Quick Ratio | 1.936 |
| Cash Ratio | 0.856 |
CRMD Profitability
| Gross Margin | 88.463 |
| Operating Margin | 48.167 |
| Pretax Margin | 48.127 |
| Net Margin | 52.31 |
| Return on Assets | 32.726 |
| Return on Equity | 66.558 |
| Return on Total Capital | 29.421 |
| Return on Invested Capital | 51.132 |
CRMD Capital Structure
| Total Debt to Total Equity | 36.741 |
| Total Debt to Total Capital | 26.869 |
| Total Debt to Total Assets | 16.968 |
| Long-Term Debt to Equity | 36.384 |
| Long-Term Debt to Total Capital | 26.608 |